喀什怎么检查出宫颈糜烂(喀什性生活时无法勃起) (今日更新中)

MOSCOW, Aug. 6 (Xinhua) -- The Arctic is getting warmer at a fast pace with the Russian Arctic sector's ice areas contracting to historically low levels, according to Russian meteorological bureau Rosgidromet.According to a Rosgidromet report cited by Itar-Tass news agency Saturday, the polar cap in the Russian sector has shrunk to the historical low registered in 2007, with no ice expected to block the Northern Seaway at least until September."Currently, Arctic navigation conditions are very favorable. By early August, navigation can be done without icebreakers almost along the entire route," said Valery Martyshchenko, head of Rosgidromet's environment pollution monitoring department.According to the Arctic and Antarctic Research Institute, the current ice cover in the Arctic Ocean is 6,860 million square kilometers, way below average.Martyshchenko said the longer period of icebreaker-free navigation would benefit the regions located in the Arctic area, allowing longer access to food and energy supplies, but the warming of the climate also posed new threats, such as melting of ice and forming of icebergs.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, Aug. 24 (Xinhuanet)-- A new study shows that a diet rich in cholesterol-friendly foods, such as soy products and tree nuts, can decrease LDL (bad) cholesterol significantly, according to media reports on Tuesday.The study, published in the Journal of the American Medical Association, found that people who ate a healthy diet filled with cholesterol-lowering foods experienced a 13 percent decrease in their LDL cholesterol levels.For patients with high levels of so-called bad cholesterol, doctors usually have two prescriptions: cholesterol-lowering statin drugs and a diet that cuts out foods high in saturated fat, such as ice cream, red meat and butter.But the new study found that when it comes to lowering artery-clogging cholesterol, what you eat may be more important than what you don't eat.David Jenkins of St. Michael's Hospital and the University created the "portfolio diet," which includes regular consumption of tree nuts and high amounts of fiber from oats, barley and vegetables. The diet, which replaces butter with plant sterol-enriched margarine and substitute soy-based products for meat, allows maximum benefit in lowering cholesterol and preventing heart disease. "The study highlighted the power of food to lower risk for cardiovascular disease: What you do eat and what you don't eat are both important," said Dr. Jane Klauer, a New York internist specializing in metabolism and nutrition.A high overall cholesterol level makes a person nearly twice as likely to suffer a heart attack or stroke as someone whose total cholesterol falls into a healthy range.

LOS ANGELES, July 19 (Xinhua) -- Obesity prevalence was 30 percent or higher in 12 states of the United States last year, compared to nine states in 2009, the Centers for Disease Control and Prevention (CDC) said on Tuesday.In 2000, no states in the country had obesity rates that high, and now obesity is a problem in all 50 states, the agency said in a report based on telephone interviews with 400,000 people.Obesity rates vary by region, led by the South at 29.4 percent, followed by the Midwest at 28.7 percent, the Northeast at 24.9 percent, and the West at 24.1 percent, the report said.Mississippi had the nation's highest obesity prevalence at 34 percent, and Colorado the lowest at 21 percent, according to the report.Alabama, Arkansas, Kentucky, Louisiana, Michigan, Mississippi, Missouri, Oklahoma, South Carolina, Tennessee, Texas, and West Virginia all had obesity rates of 30 percent or higher in 2010, said the report.No state met the federal Healthy People 2010 goal of a 15 percent obesity rate. In fact, no state had a rate lower than 20 percent, the CDC said.Obesity rates have kept rising despite a steady drumbeat of warnings that obesity causes serious health problems and increases the risk of premature death, CDC officials said.An adult is considered obese if he or she has a body mass index (BMI) of 30 or greater.

WELLINGTON, Aug. 8 (Xinhua) -- A New Zealand study has found that people who work at least 50 hours a week can be up to three times more at risk of alcohol problems than people who work fewer hours.The study, conducted by the University of Otago, used data that followed more than 1,000 people born in Christchurch in 1977 through to age 30.Study leader Dr Sheree Gibb said it aimed to examine whether working hours were related to alcohol problems in early adulthood.Data from more than 1,000 participants at ages 25 and 30 showed a significant association between longer working hours and alcohol- related problems.Longer working hours were associated with higher levels of alcohol problems including frequent alcohol use and alcohol abuse or dependence.People who worked 50 hours or more on average a week were 1.8 to 3.3 times more likely to have alcohol-related problems than those who were not working, and about 1.2 to 1.5 times more likely to have alcohol-related problems than those who worked 30 to 49 hours a week.The higher risk of alcohol abuse for those who worked longer hours was evident in both men and women, according to the study.Gibb said the finding could suggest a need for consideration of policies and programs targeting individuals who worked long hours, with the aim of reducing rates of alcohol-related problems.The article had been accepted for publication by the UK-based journal Addiction.

来源：资阳报